N-(2-adamantyl)methanesulfonamide | 130628-23-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: N-(2-adamantyl)methanesulfonamide
• CAS: 130628-23-8
• 化学式: C₁₁H₁₉NO₂S
• 分子量: 229.343
• InChiKey: QEHURIHBLSAKFS-UHFFFAOYSA-N

物化性质

• 沸点：
  349.9±25.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-adamantyl)methanesulfonamide 在 PPA 作用下， 反应 1.0h， 生成 金刚烷酮 、 金刚烷 、 金刚烷胺
  参考文献：
  名称：

  Synthesis of 13-acylamino-huprines: different behavior of diastereomeric 13-methanesulfonamido-huprines on PPA-mediated hydrolysis

  摘要：

  Two diastereomeric pairs of rationally designed huprines additionally substituted at position 13 with a formamido or an acetamido group have been synthesized as potential high affinity acetylcholinesterase inhibitors. The synthetic sequence involves hydrolysis of two diastereomeric 13-methanesulfonamido-huprines, followed by acylation of the resulting diastereomeric amines. In the hydrolysis reaction, carried out with PPA under harsh conditions, significant amounts of cyclized or rearranged by-products were also formed, depending on the stereochemistry of the starting compound. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.04.054
• 作为产物：
  描述：

  N-(1-金刚烷基)甲磺酰胺 在 PPA 作用下， 反应 1.0h， 生成 金刚烷酮 、 金刚烷 、 1-金刚烷醇 、 N-(2-adamantyl)methanesulfonamide
  参考文献：
  名称：

  Synthesis of 13-acylamino-huprines: different behavior of diastereomeric 13-methanesulfonamido-huprines on PPA-mediated hydrolysis

  摘要：

  Two diastereomeric pairs of rationally designed huprines additionally substituted at position 13 with a formamido or an acetamido group have been synthesized as potential high affinity acetylcholinesterase inhibitors. The synthetic sequence involves hydrolysis of two diastereomeric 13-methanesulfonamido-huprines, followed by acylation of the resulting diastereomeric amines. In the hydrolysis reaction, carried out with PPA under harsh conditions, significant amounts of cyclized or rearranged by-products were also formed, depending on the stereochemistry of the starting compound. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.04.054

文献信息

• ADAMANTANE ANALOGS
  申请人：DeGrado William F.

  公开号：US20120270917A1

  公开（公告）日：2012-10-25

  Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein.

  提供了能够通过与M2跨膜蛋白相互作用来调节甲型流感病毒活性的化合物。还提供了治疗甲型流感受影响疾病状态或感染的方法，包括给予一个被鉴定为能够与M2蛋白相互作用的一个或多个化合物组成的组合物。
• Fused-ring compounds, pharmaceutical composition and uses thereof
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US10202388B2

  公开（公告）日：2019-02-12

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

  本公开涉及一种式(I)的熔环化合物和/或其药学上可接受的盐、一种包含式(I)的熔环化合物和/或其药学上可接受的盐的药物组合物、其制备方法以及其在调节吲哚胺2，3-二氧化酶(IDO)和/或色氨酸2，3-二氧化酶(TDO)活性中的用途。本公开进一步提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫性疾病。
• FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US20180022752A1

  公开（公告）日：2018-01-25

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.
• US9301950B2
  申请人：——

  公开号：US9301950B2

  公开（公告）日：2016-04-05
• Synthesis of 13-acylamino-huprines: different behavior of diastereomeric 13-methanesulfonamido-huprines on PPA-mediated hydrolysis
  作者：Pelayo Camps、Elena Gómez、Diego Muñoz-Torrero

  DOI：10.1016/j.tet.2004.04.054

  日期：2004.6

  Two diastereomeric pairs of rationally designed huprines additionally substituted at position 13 with a formamido or an acetamido group have been synthesized as potential high affinity acetylcholinesterase inhibitors. The synthetic sequence involves hydrolysis of two diastereomeric 13-methanesulfonamido-huprines, followed by acylation of the resulting diastereomeric amines. In the hydrolysis reaction, carried out with PPA under harsh conditions, significant amounts of cyclized or rearranged by-products were also formed, depending on the stereochemistry of the starting compound. (C) 2004 Elsevier Ltd. All rights reserved.